BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 26514321)

  • 1. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
    Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
    Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer.
    Yang SN; Liang JA; Lin FJ; Kao CH; Lin CC; Lee CC
    J Cancer Res Clin Oncol; 2002 Jun; 128(6):325-8. PubMed ID: 12073051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer.
    Hsia TC; Shen YY; Yen RF; Kao CH; Changlai SP
    Neoplasma; 2002; 49(4):267-71. PubMed ID: 12382027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases.
    Kao CH; Hsieh JF; Tsai SC; Ho YJ; Yen RF
    Anticancer Res; 2000; 20(3B):2189-92. PubMed ID: 10928175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy.
    Ohta M; Tokuda Y; Suzuki Y; Kubota M; Makuuchi H; Tajima T; Nasu S; Suzuki Y; Yasuda S; Shohtsu A
    Nucl Med Commun; 2001 Aug; 22(8):875-9. PubMed ID: 11473206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report.
    Wu HC; Yen RF; Shen YY; Kao CH; Lin CC; Lee CC
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):503-6. PubMed ID: 12242515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer.
    Baslaim MM; Bakheet SM; Bakheet R; Ezzat A; El-Foudeh M; Tulbah A
    World J Surg; 2003 Oct; 27(10):1099-104. PubMed ID: 12917770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of fluorodeoxyglucose positron emission tomography and "conventional diagnostic procedures" for the detection of distant metastases in breast cancer patients.
    Dose J; Bleckmann C; Bachmann S; Bohuslavizki KH; Berger J; Jenicke L; Habermann CR; Jãnicke F
    Nucl Med Commun; 2002 Sep; 23(9):857-64. PubMed ID: 12195090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of occult bone metastases of lung cancer with fluorine-18 fluorodeoxyglucose positron emission tomography.
    Foo SS; Ramdave S; Berlangieri SU; Scott AM
    Australas Radiol; 2004 Jun; 48(2):214-6. PubMed ID: 15230758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions.
    Cook GJ; Houston S; Rubens R; Maisey MN; Fogelman I
    J Clin Oncol; 1998 Oct; 16(10):3375-9. PubMed ID: 9779715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients.
    Bruckmann NM; Kirchner J; Umutlu L; Fendler WP; Seifert R; Herrmann K; Bittner AK; Hoffmann O; Mohrmann S; Antke C; Schimmöller L; Ingenwerth M; Breuckmann K; Stang A; Buchbender C; Antoch G; Sawicki LM
    Eur Radiol; 2021 Nov; 31(11):8714-8724. PubMed ID: 33912991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG-PET for detection of osseous metastases from malignant primary bone tumours: comparison with bone scintigraphy.
    Franzius C; Sciuk J; Daldrup-Link HE; Jürgens H; Schober O
    Eur J Nucl Med; 2000 Sep; 27(9):1305-11. PubMed ID: 11007511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma.
    Willkomm P; Bender H; Bangard M; Decker P; Grünwald F; Biersack HJ
    J Nucl Med; 2000 Oct; 41(10):1657-63. PubMed ID: 11037995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer.
    Bury T; Barreto A; Daenen F; Barthelemy N; Ghaye B; Rigo P
    Eur J Nucl Med; 1998 Sep; 25(9):1244-7. PubMed ID: 9724372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability.
    Scheidhauer K; Scharl A; Pietrzyk U; Wagner R; Göhring UJ; Schomäcker K; Schicha H
    Eur J Nucl Med; 1996 Jun; 23(6):618-23. PubMed ID: 8662094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lytic Bony Lesions On 18 F-FDG PET-CT Versus 99m Tc MDP Bone Scan.
    Rasheed N; Razi M
    J Pak Med Assoc; 2023 Oct; 73(10):2121-2122. PubMed ID: 37876088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The value of (18)FDG-PET for the detection of infected hip prosthesis.
    Vanquickenborne B; Maes A; Nuyts J; Van Acker F; Stuyck J; Mulier M; Verbruggen A; Mortelmans L
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):705-15. PubMed ID: 12616322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between bone scintigraphy and tumor markers in patients with breast cancer.
    Yildiz M; Oral B; Bozkurt M; Cobaner A
    Ann Nucl Med; 2004 Sep; 18(6):501-5. PubMed ID: 15515750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.